BRNS
Barinthus Biotherapeutics plc.Company Information
- Company Name
- Barinthus Biotherapeutics plc.
- CIK
- CIK0001828185
- Category
- <br>Emerging growth company
- Ticker: Exchange
- BRNS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BRNS
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-06-26
- Last sale
- 2023-03-27
- Shares purchased (TTM)
- 23,750
- Shares sold (TTM)
- 75,276
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 11,685
- Shares outstanding
- 40,848,893
- Ownership
- 0.03%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 32.04%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Related Party | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Cash And Cash Equivalents At Carrying Value | 59 | 66 | 70 | 74 | 86 | 99 | 111 | 106 | 118 | 130 | 142 | 160 | ||||||
| Contract With Customer Asset Net Current | - | - | - | - | - | - | - | 15 | - | - | - | - | ||||||
| Restricted Cash Current | 0 | 1 | 1 | 1 | 2 | 1 | 2 | - | - | - | 0 | - | ||||||
| Deferred B Shares | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Deferred C Shares | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Prepaid Expense And Other Assets Current | 2 | 4 | 5 | 6 | 8 | 6 | 6 | 8 | 10 | 8 | 10 | 7 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Assets Current | 63 | 73 | 78 | 87 | 100 | 110 | 126 | 135 | 132 | 143 | 157 | 171 | ||||||
| Property Plant And Equipment Net | 3 | 3 | 4 | 5 | 5 | 6 | 7 | 11 | 11 | 12 | 12 | 12 | ||||||
| Intangible Assets Net Excluding Goodwill | 13 | 14 | 14 | 15 | 20 | 21 | 22 | 23 | 24 | 24 | 25 | 26 | ||||||
| Goodwill | - | - | - | - | - | - | 0 | 12 | 12 | 12 | 12 | 12 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 7 | 7 | 7 | 8 | 7 | ||||||
| Other Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 82 | 92 | 98 | 109 | 130 | 142 | 160 | 189 | 187 | 199 | 215 | 230 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 0 | 1 | 2 | 1 | 2 | 3 | 3 | 1 | 2 | 5 | ||||||
| Deferred Income Current | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 0 | - | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 11 | 12 | 10 | 11 | 13 | 12 | 16 | 15 | 16 | 13 | 13 | 19 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 11 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Deferred Income Tax Liabilities Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 1 | - | ||||||
| Liabilities | 25 | 26 | 24 | 25 | 27 | 26 | 30 | 29 | 30 | 27 | 28 | 34 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 395 | 394 | 394 | 393 | 394 | 394 | 393 | 392 | 390 | 389 | 387 | 386 | ||||||
| Retained Earnings Accumulated Deficit | -320 | -310 | -304 | -293 | -278 | -257 | -238 | -217 | -209 | -192 | -177 | -159 | ||||||
| Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax | -18 | -19 | -16 | -16 | -13 | -21 | -26 | -16 | -25 | -25 | -23 | -31 | ||||||
| Stockholders Equity | 57 | 66 | 74 | 84 | 102 | 116 | 130 | 159 | 157 | 172 | 187 | 195 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 82 | 92 | 98 | 109 | 130 | 142 | 160 | 189 | 187 | 199 | 215 | 230 | ||||||
| Deferred Shares. | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 41 | 41 | 41 | 41 | 40 | 40 | 40 | 40 | 39 | 39 | 39 | 39 | ||||||
| Common Stock Shares Issued | 41 | 41 | 41 | 41 | 40 | 40 | 40 | 40 | 39 | 39 | 39 | 39 | ||||||
| Shares Outstanding | 41 | 41 | 41 | 41 | 40 | 40 | 40 | 40 | 39 | 39 | 39 | 39 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBarinthus Biotherapeutics plc. (BRNS) — SEC Financial Statements & Analysis
Barinthus Biotherapeutics plc. (BRNS) is a pharmaceutical preparations company, incorporated in X0. Barinthus Biotherapeutics plc. trades on Nasdaq as: BRNS. Barinthus Biotherapeutics plc. (BRNS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, On profitability, Barinthus Biotherapeutics plc. posts an operating margin of -512.35%, a net margin of -463.88%, a Return on Equity (ROE) of -52.32%, a Return on Assets (ROA) of -39.49%, and a Return on Invested Capital (ROIC) of -689.20%. Per share, it reports EPS of $-1.02, diluted EPS of $-1.02, free cash flow per share of $-0.65, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -39.87% year-over-year, and EPS growth of -40.61% year-over-year. On the balance sheet, it maintains a current ratio of 5.54x, a quick ratio of 5.33x, working capital of $51.85M, a debt-to-equity ratio of 0.43x, a debt ratio of 0.3, an interest coverage ratio of -825.00x, free cash flow of $-26.43M (TTM), and net debt of $-59.63M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-1.02
- ROE TTM
- -52.32%
- ROA TTM
- -39.49%
- Debt To Equity
- 0.43x
- Free Cash Flow TTM
- $-26.43M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Barinthus Biotherapeutics plc. in?
Barinthus Biotherapeutics plc. (BRNS) operates in the Pharmaceutical Preparations industry.
What exchange does BRNS trade on?
Barinthus Biotherapeutics plc. (BRNS) trades on the Nasdaq.
Where is Barinthus Biotherapeutics plc. incorporated?
Barinthus Biotherapeutics plc. is incorporated in United Kingdom.
When was Barinthus Biotherapeutics plc. (BRNS)'s most recent SEC filing?
Barinthus Biotherapeutics plc. (BRNS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is BRNS's EPS (earnings per share)?
Barinthus Biotherapeutics plc. (BRNS)'s trailing twelve month EPS is $-1.02 as of 2026-06-30.
What is BRNS's ROE (return on equity)?
Barinthus Biotherapeutics plc. (BRNS)'s trailing twelve month Return on Equity (ROE) is -52.32% as of 2026-06-30.
What is BRNS's ROA (return on assets)?
Barinthus Biotherapeutics plc. (BRNS)'s trailing twelve month Return on Assets (ROA) is -39.49% as of 2026-06-30.
What is BRNS's ROIC (return on invested capital)?
Barinthus Biotherapeutics plc. (BRNS)'s trailing twelve month Return on Invested Capital (ROIC) is -689.20% as of 2025-12-31.